WaveMan
WaveMan · Company
JAZZ · Jazz Pharmaceuticals Plc
> Search tickers & screens ⌘K
LIVE
← All companies

JAZZ Jazz Pharmaceuticals (JAZZ) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001232524
Quote by TradingView
Form 144 · 21
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
378
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $8.9M priced

What the filings say about JAZZ

Insiders, 180 days
-$32.5M net sold
8 sellers · 52% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$38.5M
21 notices

Jazz Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Jazz Pharmaceuticals plc insiders sold a net $32.5M of stock across 255 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
GALA RENEE D
President & CEO
SELL
2026-10-07 SECtraded 2026-10-06
2,000
$472.8K
-7.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 8, 2026.
  • The trade is 1.4% of the 141,394 shares held after it.
  • 2 other insiders sold within 30 days.
  • 378 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO GALA RENEE D sold about $472.8K of JAZZ under a 10b5-1 plan on Oct 6, 2026; 2 other insiders sold within 30 days and 378 funds added in the latest 13F quarter.
COZADD BRUCE C
Director
SELL
2026-10-05 SECtraded 2026-10-01
6,000
$1.4M
-11.1%
Context
  • 94 earlier Form 4 trades (code P or S) here by this insider (94 sales), the last on Sep 1, 2026.
  • The trade is 1.7% of the 345,875 shares held after it.
  • 2 other insiders sold within 30 days.
  • 378 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director COZADD BRUCE C sold about $1.4M of JAZZ under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 378 funds added in the latest 13F quarter.
Patil Neena M
EVP & Chief Legal Officer
SELL
2026-09-14 SECtraded 2026-09-10
1,200
$289.1K
-14.6%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Jun 10, 2026.
  • The trade is 2.5% of the 47,671 shares held after it.
  • 3 other insiders sold within 30 days.
  • 378 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Legal Officer Patil Neena M sold about $289.1K of JAZZ under a 10b5-1 plan on Sep 10, 2026; 3 other insiders sold within 30 days and 378 funds added in the latest 13F quarter.
GALA RENEE D
President & CEO
SELL
2026-09-10 SECtraded 2026-09-08
2,000
$486.1K
-16.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 18, 2023.
  • The trade is 1.4% of the 143,394 shares held after it.
  • 3 other insiders sold within 30 days.
  • 378 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO GALA RENEE D sold about $486.1K of JAZZ under a 10b5-1 plan on Sep 8, 2026; 3 other insiders sold within 30 days and 378 funds added in the latest 13F quarter.
COZADD BRUCE C
Director
SELL
2026-09-02 SECtraded 2026-09-01
6,000
$1.5M
-16.9%
Context
  • 93 earlier Form 4 trades (code P or S) here by this insider (93 sales), the last on Aug 3, 2026.
  • The trade is 1.7% of the 351,875 shares held after it.
  • 3 other insiders sold within 30 days.
  • 378 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director COZADD BRUCE C sold about $1.5M of JAZZ under a 10b5-1 plan on Sep 1, 2026; 3 other insiders sold within 30 days and 378 funds added in the latest 13F quarter.
255 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 250 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$32.5M over 180 days
-$24.9M over 90 days
below 92% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
378 funds bought in last quarter
more than 96% of Pharma & Biotech
Revenue
+4.9% year over year
more than 53% of Pharma & Biotech
Margin
-8.3% net margin
more than 65% of Pharma & Biotech
Buybacks
$125.0M repurchased, FY to 2025-12-31
more than 69% of Pharma & Biotech
Short interest
9.3% of the float short (float per yahoo 2026-10-27) · 6.9 days to cover · settled 2026-10-15
more than 68% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 8Director ANNE O'RIORDAN filed to sell $3.4M by Oct 8 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 7President & CEO GALA RENEE D sold $472.8K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Officer RENEE D GALA filed to sell $472.8K by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 5Director COZADD BRUCE C sold $1.4M under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer Bruce C Cozadd filed to sell $1.4M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch JAZZ

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+48.9%12M
-5%+26%+58%+89%2025-102025-122026-022026-042026-062026-082026-10 2025-11-26 · COZADD BRUCE C sold $6.8M2025-11-26 · COZADD BRUCE C sold $5.4M2026-08-27 · Iannone Robert sold $4.9M2026-08-27 · Iannone Robert sold $4.5M2026-08-27 · Iannone Robert sold $4.5M2026-02-26 · Patil Neena M sold $3.2M2026-02-26 · Patil Neena M sold $3.0M2026-08-27 · Iannone Robert sold $2.8M2026-08-27 · Iannone Robert sold $2.3M2026-02-26 · Patil Neena M sold $2.2M2026-05-28 · Pearce Samantha sold $1.6M2026-08-03 · COZADD BRUCE C sold $1.5M2025-11-18 · COZADD BRUCE C sold $1.5M2025-11-26 · COZADD BRUCE C sold $1.5M2026-09-01 · COZADD BRUCE C sold $1.5M2026-07-01 · COZADD BRUCE C sold $1.4M2026-06-01 · COZADD BRUCE C sold $1.4M2026-10-01 · COZADD BRUCE C sold $1.4M2026-05-01 · COZADD BRUCE C sold $1.2M2025-11-17 · Iannone Robert sold $1.2M2026-02-26 · Henderson Mary Elizabeth sold $1.0M2025-11-18 · COZADD BRUCE C sold $1.0M2025-11-18 · Winningham Rick E sold $994.7K2025-11-18 · Carr Patricia sold $955.9K2025-12-05 · Carr Patricia sold $770.4K2026-04-01 · COZADD BRUCE C sold $700.8K2026-02-26 · Patil Neena M sold $682.0K2026-05-22 · Winningham Rick E sold $662.1K2026-02-27 · RIEDEL NORBERT G sold $655.7K2025-11-18 · COZADD BRUCE C sold $609.4K2025-11-20 · McSharry Heather Ann sold $607.1K2026-03-03 · COZADD BRUCE C sold $587.9K2026-02-26 · Patil Neena M sold $553.5K2026-03-03 · COZADD BRUCE C sold $487.0K2026-09-08 · GALA RENEE D sold $486.1K2026-05-22 · McSharry Heather Ann sold $482.0K2026-10-06 · GALA RENEE D sold $472.8K2026-04-01 · COZADD BRUCE C sold $437.6K2025-12-09 · Henderson Mary Elizabeth sold $379.4K2026-02-26 · Patil Neena M sold $342.3K2026-09-10 · Patil Neena M sold $289.1K2026-05-28 · Patil Neena M sold $282.5K2026-10-08 · ANNE O'RIORDAN filed to sell $3.4M2026-10-06 · RENEE D GALA filed to sell $472.8K2026-10-01 · Bruce C Cozadd filed to sell $1.4M2026-09-10 · NEENA PATIL filed to sell $289.1K2026-09-08 · RENEE D GALA filed to sell $486.1K2026-09-08 · Henderson Mary Elizabeth filed to sell $664.2K2026-09-01 · Bruce C Cozadd filed to sell $1.5M2026-08-31 · COZADD BRUCE C filed to sell $612.8K2026-08-31 · Cook Jennifer E. filed to sell $857.6K2026-08-31 · ENRIGHT PATRICK G filed to sell $857.6K2026-08-31 · Hamill Laura filed to sell $857.6K2026-08-31 · Henderson Mary Elizabeth filed to sell $942.0K2026-08-31 · RIEDEL NORBERT G filed to sell $857.6K2026-08-31 · LOVE TED W filed to sell $373.4K2026-08-31 · Winningham Rick E filed to sell $857.6K2026-08-31 · McSharry Heather Ann filed to sell $857.6K2026-08-31 · Smith Mark Douglas filed to sell $857.6K2026-08-31 · Kennedy Patrick filed to sell $857.6K2026-08-27 · ROBERT IANNONE filed to sell $19.2M2026-08-07 · ORiordan Anne filed to sell $882.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns JAZZ: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
5,968,603 sh
$1.4B
FMR LLC
4,609,326 sh
$1.1B
VANGUARD PORTFOLIO MANAGEMENT LLC
3,036,213 sh
$731.6M
VANGUARD CAPITAL MANAGEMENT LLC
2,729,650 sh
$657.8M
Capital World Investors
2,697,610 sh
$650.0M

Congress trades in JAZZ

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

JAZZ planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ANNE O'RIORDAN
Filed 2026-10-08
$3.4M
RENEE D GALA
Filed 2026-10-06
$472.8K
Bruce C Cozadd
Filed 2026-10-01
$1.4M
NEENA PATIL
Filed 2026-09-10
$289.1K
RENEE D GALA
Filed 2026-09-08
$486.1K

JAZZ mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Saratoga Health & Biotechnology Fund
$648.2K position · as of 2026-05-31
6.2%
LIVE OAK HEALTH SCIENCES FUND
$3.2M position · as of 2026-07-31
5.8%
Quantified Common Ground Fund
$5.0M position · as of 2026-06-30
4.2%
ROCK OAK CORE GROWTH FUND
$548.5K position · as of 2026-07-31
4.0%
DEAN MID CAP VALUE
$9.6M position · as of 2026-06-30
3.5%
iShares U.S. Pharmaceuticals ETF
$39.3M position · as of 2026-06-30
3.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
93 registered trials, 25 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
18
Phase 1
6 active
19
Phase 2
5 active
35
Phase 3
6 active
7
Phase 4
2 active
9
Not applicable
4 active
5
Multi-phase
2 active
What changed recently
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZ
2026-10-24 · Completion moved 2026-07-05 → 2026-11-30
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZ
2026-10-24 · Recruiting → Active Not Recruiting
Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neopla
2026-10-24 · Completion moved 2026-07 → 2027-03-31
Phase 1
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juven
2026-10-07 · Not Yet Recruiting → Recruiting
PHASE2,PHASE3
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid
2026-09-11 · Recruiting → Active Not Recruiting
Phase 1
Child and Adolescent Registry for Participants With Narcolepsy
2026-09-03 · Recruiting → Unknown
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Jazz Pharmaceuticals, Inc. Political Action Committee
Cycle 2026 · $194K spent
$144.4K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Renee D. Gala
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$15.5M
$17.3M
$4.7M
-25%
-7%
2023
$15.3M
-$2.5M
$4.2M
-25%
-6%
2022
$17.3M
$26.3M
$5.0M
-3%
-10%
2021
$15.7M
$4.9M
$4.5M
-23%
+0%
2020
$12.6M
$19.6M
$4.1M
+11%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $32.5M sold by insiders over 180 days, 378 funds added last quarter, $38.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

JAZZ financials

Revenue growth
+4.9%
XBRL, annual
Net margin
-8.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.6B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+20.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$1.6B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.91x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.38x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+22.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+8.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
effective tax rate -29%, not meaningful
Return on capital employed
+10.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
14.06x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$16.1B
market value at close 2026-10-26 on 2026-07-27 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+11.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$4.3B$4.1B$3.8B$3.7B
Operating income-$430.2M$716.6M$578.6M-$65.5M
Net income-$356.1M$560.1M$414.8M-$224.1M
EPS (diluted)-5.848.656.10-3.58
Operating cash flow$1.4B$1.4B$1.1B$1.3B
Cash$1.4B$2.4B$1.5B$881.5M
Long-term debt$4.3B$6.1B$5.1B$5.7B
Buybacks$125.0M$311.4M$269.8M$54.0K
SEC XBRL, fiscal years, as known on 2026-10-28

JAZZ Stock Sonar score 6/7 axes

Find similar shapesCompare

JAZZ ranks highest on institutional and government (91st percentile) and profitability (89th), and lowest on insider conviction (7th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
89
Inputs
  • Return on equity+22.1% · 90 pct, sector of 545
  • Return on assets+8.5% · 88 pct, sector of 691
  • Return on invested capitaleffective tax rate -29%, not meaningful
  • Return on capital employed+10.1% · 90 pct, sector of 576
Financial health
54
Inputs
  • Debt to equity0.91x · 21 pct, sector of 352
  • Cash flow to debt0.38x · 87 pct, sector of 371
Growth
53
Inputs
  • Revenue growth, YoY+4.9% · 53 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
7
Inputs
  • Net Form 4 buying (codes P and S), 180d-$9.2M · 15 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
91
Inputs
  • Funds adding, latest quarter378 · 96 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$2.8M · 86 pct, sector of 133
Risk and compliance
32
Inputs
  • Short interest, % of float+9.3% · 41 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+17.8% · 23 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

JAZZ filings, in plain words

Are Jazz Pharmaceuticals insiders buying or selling JAZZ?

In the 180 days to 2026-10-28, Jazz Pharmaceuticals insiders were net sellers, a net $32.5M across purchases and sales reported on Form 4, by 8 sellers.

Are there planned insider sales of JAZZ?

Yes. 21 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $38.5M of stock; the latest, by ANNE O'RIORDAN, was filed 2026-10-08.

Read the full summary

In the 180 days to 2026-10-28, Jazz Pharmaceuticals insiders were net sellers of JAZZ, a net $32.5M across purchases and sales reported on Form 4 by 8 sellers. 52% of the 21 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 21 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $38.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies